<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01084824</url>
  </required_header>
  <id_info>
    <org_study_id>NID-001</org_study_id>
    <nct_id>NCT01084824</nct_id>
  </id_info>
  <brief_title>A Trial Examining the Treatment of Common Warts With Combination Liquid Nitrogen (LN2) and Cantharidin</brief_title>
  <official_title>A Randomized Clinical Trial Examining the Efficacy of Treatment of Cutaneous Verruca Vulgaris in Adult Patients With Combined Liquid Nitrogen Cryotherapy and Topically Applied Cantharidin</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>North Idaho Dermatology</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>North Idaho Dermatology</source>
  <brief_summary>
    <textblock>
      The purpose of the study was to see if liquid nitrogen, a commonly used treatment for warts,
      is more effective if it is used alone, or if it is more effective if combined with
      cantharidin, a topical treatment also commonly used for warts (verruca vulgaris).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2007</start_date>
  <completion_date type="Actual">September 2008</completion_date>
  <primary_completion_date type="Actual">June 2008</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of common warts cleared</measure>
    <time_frame>12 weeks</time_frame>
    <description>Percentage of treated warts cleared with treatment, as measured with dermatoscopic examination, after 12 weeks.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">70</enrollment>
  <condition>Verruca Vulgaris</condition>
  <arm_group>
    <arm_group_label>Liquid nitrogen and canthardin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Liquid nitrogen applied to wart(s), then cantharidin 1% topical applied afterwards.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Liquid nitrogen and placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Liquid nitrogen applied to wart(s) then placebo vehicle afterwards.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Liquid nitrogen and cantharidin</intervention_name>
    <description>Liquid nitrogen applied to wart(s), then cantharidin 1% topical applied afterward.</description>
    <arm_group_label>Liquid nitrogen and canthardin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Liquid nitrogen and topical placebo</intervention_name>
    <description>Liquid nitrogen applied to wart(s), then placebo vehicle applied thereafter.</description>
    <arm_group_label>Liquid nitrogen and placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. common warts on non-genital, non-facial skin

          2. otherwise healthy

          3. between 18-65 and able to give informed consent

          4. capable of tolerating treatment

        Exclusion Criteria:

          1. Ill-health

          2. Poor tolerance or sensitivity to treatments in study

          3. &lt;18 years old; &gt;65 years old

          4. verruca plana or condyloma acuminata

          5. immunosuppression or immune dysfunction

          6. significant peripheral vascular disease

          7. significant sensitivity to cold

          8. epidermodysplasia verruciformis

          9. mosaiform warts or periungual warts
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Richard A Flygare, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>TUI University; North Idaho Dermatology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>North Idaho Dermatology</name>
      <address>
        <city>Coeur D'Alene</city>
        <state>Idaho</state>
        <zip>83814</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Berth-Jones J, Bourke J, Eglitis H, Harper C, Kirk P, Pavord S, Rajapakse R, Weston P, Wiggins T, Hutchinson PE. Value of a second freeze-thaw cycle in cryotherapy of common warts. Br J Dermatol. 1994 Dec;131(6):883-6.</citation>
    <PMID>7857844</PMID>
  </reference>
  <reference>
    <citation>Guidelines of care for cryosurgery. American Academy of Dermatology Committee on Guidelines of Care. J Am Acad Dermatol. 1994 Oct;31(4):648-53.</citation>
    <PMID>8089292</PMID>
  </reference>
  <reference>
    <citation>Moed L, Shwayder TA, Chang MW. Cantharidin revisited: a blistering defense of an ancient medicine. Arch Dermatol. 2001 Oct;137(10):1357-60. Review.</citation>
    <PMID>11594862</PMID>
  </reference>
  <verification_date>March 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 10, 2010</study_first_submitted>
  <study_first_submitted_qc>March 10, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 11, 2010</study_first_posted>
  <last_update_submitted>March 10, 2010</last_update_submitted>
  <last_update_submitted_qc>March 10, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 11, 2010</last_update_posted>
  <responsible_party>
    <name_title>Richard Flygare, Ph.D.; Stephen Craig, M.D.</name_title>
    <organization>North Idaho Dermatology, TUI University</organization>
  </responsible_party>
  <keyword>Warts</keyword>
  <keyword>Verruca vulgaris</keyword>
  <keyword>Liquid Nitrogen</keyword>
  <keyword>Cantharidin</keyword>
  <keyword>combination treatment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Warts</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cantharidin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

